GlassScriptPhysician profile
Joseph Payne
NPI 1831189398
$710,572.53
in general payments reported to CMS, 2019-2025
42 companies · $134K in 2025
The $134K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $45K · 2021: $23K · 2022: $87K · 2023: $108K · 2024: $141K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $327K · Travel and Lodging: $25K · Food and Beverage: $15K · Consulting Fee: $14K · Education: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $326,950.85 |
| Travel and Lodging | $24,943.77 |
| Food and Beverage | $15,392.31 |
| Consulting Fee | $14,297.50 |
| Education | $645.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306,693.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $138,252.02 | 2019-2025 | Cosentyx |
| Ucb, INC. | $110,977.63 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $52,443.86 | 2020-2022 | |
| Janssen Biotech, INC. | $43,746.28 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $29,287.99 | 2022-2025 | Sotyktu |
| Pfizer INC. | $18,124.44 | 2019-2025 | |
| Genzyme Corporation | $2,392.25 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,480.34 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $1,462.62 | 2019-2025 | Dupixent |
| Leo Pharma As | $1,128.10 | 2024 | |
| Lilly USA, LLC | $765.25 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $657.01 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Sun Pharmaceutical Industries INC. | $635.01 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $412.88 | 2021-2023 | Adbry |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $303.22 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $226.62 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.29 | 2020-2024 | Siliq, Targretin, Duobrii |
| Organogenesis INC. | $137.24 | 2023-2025 | Affinity, Puraply, Simplimax |
| Mallinckrodt Hospital Products INC. | $129.80 | 2025 | Acthar |
| Allergan, INC. | $129.34 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $114.70 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $98.06 | 2019-2021 | |
| Amgen INC. | $97.04 | 2020-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $96.42 | 2024 | Daxxify |
| Journey Medical Corporation | $92.83 | 2022-2025 | |
| Almirall LLC | $85.41 | 2021-2025 | Seysara |
| United Orthopedics LLC | $83.89 | 2024 | |
| Biofrontera INC. | $81.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.04 | 2022-2024 | Spevigo |
| Botanix Sb INC | $41.91 | 2025 | Sofdra |
| Ani Pharmaceuticals, INC. | $35.29 | 2025 | Sovuna, Oxistat |
| Vyne Pharmaceuticals INC. | $26.69 | 2020 | |
| Mylan Pharmaceuticals INC. | $25.75 | 2019 | |
| Organon LLC | $22.35 | 2023-2025 | Vtama, Hadlima |
| Fresenius Kabi USA, LLC | $16.31 | 2023 | Idacio |
| Nabriva Therapeutics, Plc | $15.69 | 2022 | |
| Surgenex LLC | $15.64 | 2025 | Renograft, Pellograft, Surmatrix |
| Epi Health, LLC | $15.44 | 2021 | |
| Strata Skin Sciences, INC. | $10.81 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.